Ideas
Partners
Consultants
Calls
EU Projects
Blog NEW
- Europe towards City Innovation Hubs
  
  Written by Matteo Satta EU funding has always helped cities support their innovation processes, particularly on digital transformation and environment, but the approach is now moving toward a new ambitious […]
- Mistakes that Cities Should Be Avoiding in EU Projects
  
  By Matteo Satta Nowadays, we are seeing an increasing trend of people requesting to lower taxes and, as a result, public budgets. This leads many cities to try to find […]
- How a city can boost your Smart City project
  
  By Matteo Satta The commission has been heavily investing in pilot Smart City projects for a long time, but you may often have R&D or innovation projects pretending to have […]
- How to involve a city in your project? Here are a few tips.
  
  Article written by Matteo Satta (Smart) City projects are more and more funded by the European Commission, but consortia often struggle to get cities on board or really engage them. […]
- >> See all posts
Log In Sign Up

Want to see this project on homepage?
Propose a Picture

Point-of-care microfluidic device for quantification of chemotherapeutic drugs in small body fluid samples by highly selective nanoparticle extraction and liquid crystal detection (DiaChemo)
Start date: May 1, 2015, End date: Apr 30, 2019 PROJECT FINISHED

The decision-making in chemotherapy nowadays depends on standard methods that are liquid chromatography (LC-MS/MS) followed by mass spectrometry or capillary electrophoresis; both are labour- and cost-intensive and can be performed only in dedicated hospitals and laboratories. This lead to a minimal therapeutic drug monitoring in patients and hence that 30-60% of drugs are administered without clinical benefits. We propose to develop a point-of-care device for quantification of chemotherapeutic drugs in small body fluid samples by highly selective nanoparticle extraction and liquid crystal detection incorporated in microfluidic lab-on-chip device (optofluidics based) allowing the real-time drug monitoring. This will improve the therapeutic outcome and reduced health care costs.